NCT06851559View on ClinicalTrials.gov

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

Vonoprazan

Vonoprazan will be administered orally as a tablet

DRUG

Placebo

Placebo will be administered orally as tablet

Sponsors
All Listed Sponsors
lead

Phathom Pharmaceuticals, Inc.

INDUSTRY